This site is intended for US Healthcare Professionals only.
Are You a US Healthcare Professional?
This site is intended for US healthcare professionals only. By clicking “YES,” you are declaring and confirming that you are a healthcare professional and have read and understood this disclaimer.
Activated Factor XII Is a New Target in Advancing Hereditary Angioedema Treatment1
The underlying cause of angioedema in hereditary angioedema (HAE) is dysregulation of the inflammatory, bradykinin-producing contact activation pathway.3
Tap hotspots to explore
The underlying cause of angioedema in hereditary angioedema (HAE) is dysregulation of the inflammatory, bradykinin-producing contact activation pathway.3
Tap hotspots to explore
Currently, no therapies target factor XIIa. Ongoing developments are focused on addressing this point at the top of the contact activation pathway.1,2
Follow the latest developments
Sign up to receive updates on a therapy addressing the top of the contact activation pathway.
*Required fields
Thank you!
We will send additional information as soon as it becomes available.
Share this page with your colleagues
ShareReferences: 1. Craig TJ et al. Lancet. 2023;401(10382):1079-1090. 2. Busse P, Kaplan A. J Allergy Clin Immunol Pract. 2022;10(3):716-722. 3. López Lera A. Balkan Med J. 2021;38(2):82-88. 4. Busse PJ, Christiansen SC. Hereditary Angioedema. N Engl J Med. 2020;382(12):1136-1148.
